At the time of writing, Black Diamond Therapeutics Inc [BDTX] stock is trading at $3.87, up 6.91%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BDTX shares have gain 1.31% over the last week, with a monthly amount drifted -1.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 04, 2025, and set its price target to $8. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $20 on July 31, 2024. Piper Sandler initiated its recommendation with an Overweight. Stifel upgraded its rating to Buy for this stock on June 30, 2023, and upped its price target to $10. In a note dated June 28, 2023, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $11.
For the past year, the stock price of Black Diamond Therapeutics Inc fluctuated between $1.20 and $4.45. Currently, Wall Street analysts expect the stock to reach $8 within the next 12 months. Black Diamond Therapeutics Inc [NASDAQ: BDTX] shares were valued at $3.87 at the most recent close of the market. An investor can expect a potential return of 106.72% based on the average BDTX price forecast.
Analyzing the BDTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.07%, Pretax Profit Margin comes in at 0.2%, and Net Profit Margin reading is 0.2%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.69 points at the first support level, and at 3.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.00, and for the 2nd resistance point, it is at 4.14.
Ratios To Look Out For
It is important to note that Black Diamond Therapeutics Inc [NASDAQ:BDTX] has a current ratio of 8.73. Further, the Quick Ratio stands at 8.73, while the Cash Ratio is 1.78. Considering the valuation of this stock, the price to sales ratio is 3.15, the price to book ratio is 1.66 and price to earnings (TTM) ratio is 16.34.
Transactions by insiders
Recent insider trading involved BIOTECH GROWTH N V, 10% Owner, that happened on Mar 19 ’25 when 5.78 million shares were sold.
